This is to inform you that the Board of Directors of the Company at its meeting held on June 17 2022 has approved the acquisition of 51% equity shares in GLS Pharma Limited operating in oncology business and having manufacturing facility in Hyderabad for a total consideration of INR 28 05 00 000. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and Part A of Schedule III of the aforesaid regulations is attached as Annexure A.
Ask Value Research 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
